Only a small fraction of rare pediatric designations have led to vouchers, new FDA analysis shows
Out of hundreds of potential drugs with rare pediatric disease designations, only 7% of them have won priority review vouchers from the FDA, according to …
Sign up to read this article for free.
Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.